ALXN: Alexion Pharmaceuticals, Inc. - Summary | Jitta

Alexion Pharmaceuticals, Inc.

NASDAQ:ALXN

Notice
Stock's price has been unchanged for more than a week.
Price
$182.50
Loss Chance
41.8%
7.19JITTA SCORE
50.64%Under Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (69)
Recent Business Performance (87)
Financial Strength (86)
Return to Shareholders (52)
Competitive Advantage (85)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 3 years
Operating MarginExpansion
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Recent Business PerformanceEarning decline 11.91% in the last year
Cash Conversion CycleMore than 1 year
Key Stats
Jitta Score
Jitta Line
7.19
50.64%
1.43
197.95%
2.25
348.40%
Biotechnology
6.28
43.68%
4.83
30.68%
5.90
70.35%
COMPANY DESCRIPTION
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.